NAC alone showed a significantly lower Ki-67 immunolabeling compared to the Anta group (Fig
Following the publication of pivotal randomized clinical trials (RCTs) on dapagliflozin and empagliflozin, clinical guidelines have updated their recommendations, now endorsing these agents as first-line therapy for HF, regardless of ejection fraction [11,12,13,14,15]
Many side effects can often be managed with proper dose escalation, hydration, nutrition counseling, and regular follow-up
Longevity Pathway Research Explored in studies focused on healthy aging markers and long-term cellular maintenance
Keratosis pilaris is known to occur during pregnancy and in the months following childbirth